The biotech has met with UK regulators to discuss a marketing authorization application under exceptional circumstances based on data from 11 patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback